Prof. Robert I. Glazer

powered by
COS Expertise®
Georgetown University
Pharmacology
ProfessorAppointed: 1989
Georgetown University
Oncology
ProfessorAppointed: 1999
Professional Headshot of Robert I. Glazer

Mailing Address

3970 Reservoir Road, NW
Georgetown University
Research Building
Room W318
Washington, District of Columbia 20007
United States

Contact Information

Phone: (202) 687-8324
Fax: (202) 687-7505
glazerr@georgetown.edu

Qualifications

Ph.D., Indiana University, Pharmacology, 1970.
M.S., Columbia University, Pharmacology, 1967.
B.S., Columbia University, Pharmacy, 1965.

Expertise and Research Interests

Anticancer drug development and pharmacology
Signal transduction in cancer
Recombinant protein expression
Protein kinases
Antisense oligonucleotides
Retrovirus technology
Transgenic animals
Mammary stem cells

Research interests:
Transgenic animal and primary tumor models of breast cancer
Transformation and invasion signaling pathways associated with the serine/threonine-protein kinases, Akt, PKC and PDK1
Nuclear hormone receptor PPAR-gamma and -delta and their role in the chemoprevention of breast cancer
Function of stem cell antigen-1 (Sca-1) in mammary tumorigenesis
Role of Musashi1 in breast stem cell proliferation

Other Expertise

Production of recombinant proteins for Life Technologies, Inc. and Upstate Biotechnology, Inc.
Preclinical toxicology studies for ICN Pharmaceuticals, Inc.
Preclinical assessment of antisense oligonucleotides in tumor xenograft models for Isis Pharmaceuticals, Inc., Hybridon, Inc. and Eli Lilly
High throughput assay development with Morphochem AG and Upstate Biotechnology, Inc.
DNA and protein array development with SuperArray, Inc.
Consultant to Daiichi-Sankyo on preclinical and clinical anticancer drug development
Consultant to Novartis on anticancer drug development

Future Research

Development of small molecule inhibitors of unique tumor stem cell targets

Industrial Relevance

Experience in preclinical testing of anticancer drugs and antisense oligonucleotides using human tumor xenograft models
Evaluation of signal tranduction pathways as potential drug targets
Surrogate markers of drug efficacy
Recombinant protein production using baculovirus technology

Keywords

COS Keywords:

Animal Models, Antineoplastic Agents, Biochemistry, Breast Cancer, Chemoprevention, Chemopreventive Agents, Disease Model, Molecular Biology, Oncology, Pharmacology, Signal Transduction, Transgenic Animals.

Additional Terms:

Akt/protein Kinase B, Antisense Nucleic Acid, C-Fes Tyrosine Kinase, Chemoprevention, Drug Development, Glioblastoma Multiforme, Insulinlike Growth Factor, Mammary Carcinogenesis, Mammary Stem Cells, Multidrug Resistance, Musashi1, Nucleoside Anticancer Agents, P Glycoprotein, PDK1/3-Phosphoinositide-Dependent Protein Kinase -1, Peroxisome Proliferator-activated Receptor (PPAR), Protein Kinase C, Transgenic Breast Cancer Models.

Memberships

American Association for Cancer Research
American Association for the Advancement of Science
American Society for Biochemistry and Molecular Biology
American Society for Pharmacology and Experimental Therapeutics

Honors and Awards

1996, Raymond R. Paradise Distinguished Alumni Professorship, Department of Pharmacology, Indiana University School of Medicine
1992-1994, Shannon Award, NIH
1988-1993, Bristol-Myers Drug Resistance Award, Bristol-Myers Co.
1987-1989, Intramural NIH Research Grant for AIDS Targeted Antiviral Agents, NIH
1981, Special Achievement Award, National Cancer Institute, NIH
1973-1975, Faculty Development Award, Pharmaceutical Manufacturer's Association Foundation
1970-1972, Postdoctoral Fellowship, National Cancer Institute, NIH

Previous Positions

1977-1989, Chief, National Cancer Institute, Applied Pharmacology Section
1972-1977, Assistant Professor, Emory University, School of Medicine, Pharmacology
1970-1972, Postdoctoral Fellow, Yale University, School of Medicine, Pharmacology

Patents

Method of Use of Peroxisome Proliferator-Activated Receptor Antagonists for the Treatment of Breast Cancer, Patent Number: US-2008-0206194-A1 pending, 2008, Self-owned, United States of America.
Musashi1 as a Target for Anticancer Drug Development, Patent Number: pending, 2008, Institution, United States of America.
RNA Probe for Detecting c-fes mRNA, Patent Number: 5879882, 1999, Institution-owned, United States of America.
3-Deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it, Patent Number: 4968690, 1990, Institution-owned, United States of America.
Antiviral and anticancer cyclopentenyl cytosine, Patent Number: 4975434, 1990, Institution-owned, United States of America.

Funding Received

  • Joan's Legacy Foundation: Musashi1 as a Stem Cell Marker and Therapeutic Target in Bronchioalveolar Lung Cancer, 2009 to 2011.
  • National Institutes of Health (NIH): Screening for Chemopreventive Agents Targeting Mammary Stem and Progenitor Cells in Carcinogen-Induced, Estrogen Receptor-Positive Breast Cancer, 2007 to 2009.
  • National Institutes of Health (NIH): PDK1 and PPAR-delta Signaling in Mammary Tumorigenesis, 2006 to 2011.
  • Charlotte Geyer Foundation: Notch in Initiation and Maintenance of Tumorigenesis, 2006 to 2007.
  • Sankyo Co., Ltd.: Preclinical Studies of CS-7017, 2006 to 2007.

Publications

  • Byers, S., Pishvaian, M., Mishra, L., Glazer, R.I. (2009) Cancer Stem Cells, TGF-beta, Notch and Wnt in Normal and Malignant Stem Cells: Differentiating agents and Epigenetic Modulation, New York, NY, Cambridge University Press, In Press
  • Yin, Y., Yuan, H., Zeng, X., Kopelovich, L., Glazer, R.I. (2009) Inhibition of peroxisome proliferator-activated receptor-gamma increases estrogen receptor-dependent tumor specification, Cancer Res, 69, 687-94
  • Glazer, R.I., Yuan, H., Xie, Z., Yin, Y. (June 12, 2008) PPAR-gamma and PPAR-delta as modulators of neoplasia and cell fate, PPAR Res., Article ID 247379, 8 pages
  • Glazer, R.I., Wang, X., Yuan, H., Yin, Y. (2008) Musashi1: a stem cell marker no longer in search of a function, Cell Cycle, 7, 2635-2639
  • Lindsay, J., Jiao, X., Sakamaki, T., Casomiro, M.C., Shirley, L.A., Tran, T.H., Ju, X., Liu, M., Li, Z., Wang, C., Katiyar, S., Rao, M., Allen, K.G., Glazer, R.I., Ge, C., Stanley, P., Lisanti, M.P., Rui, H., Pestell, R.G. (2008) ErbB2 induces Notch1 activity and function in breast cancer cells, Clin. Transl. Sci., 1, 107-115
  • Wang, X. (2008) Musashi-1 modulates mammary stem cell expansion through proliferin-mediated activation of the Wnt and Notch pathways, Mol. Cell. Biol., 28, 3589-3599
  • Smee, D.F., Hurst, B.L., Wong, M.H., Glazer, R.I., Rahman, A., Sidwell, R.W. (2007) Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus, Antiviral Res., 76, 124-129
  • Glazer, R.I., Wang, X., Yuan, H., Yin, Y. (2007) Mammary stem and progenitor cell regulation, Cancer Biomarkers, 3, 1-11
  • Herschkowitz, J.I., Simin, K., Weigman, V.J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K.E., Jones, L.P., Assefnia, S., Chandrasekharan, S., Backlund, M.G., Yin, Y., Khramtsov, A.I., Bastein, R., Quakenbush, J., Glazer, R.I., Brown, P.H., Green, J.E., Kopelovich, L., Furth, P.A., Palazzo, J.P., Olopade, O.I., Bernard, P.S., Churchill, G.A., Van Dyke, T., Perou, C.M. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors, Genome Biology, 8, R76.1-R76.17
  • Koller, E., Propp, S., Chang, M.Y., Hirsh, S., Zhang, H., Shepard, P.J., Koo, S.J., Murphy, C., Glazer, R.I., Dean, N.M., Inhibition of Eg5 (kinesin-like 1) with chemically modified antisense oligonucleotides leads to cell cycle arrest and antitumor activity against human tumor xenografts, Cancer Res., 66, 2059-2066, 2006
  • Xie, Z., Yuan, H., Yin, Y., Bai, R., Glazer, R.I., 3-Phosphoinositide-dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases, BMC Cancer, In Press, 2006
  • Yin, Y., Yuan, H., Wang, C., Pattabiraman, N., Rao, M., Pestell, R.G., Glazer, R.I. (2006) 3-Phosphoinositide-dependent protein kinase-1 activates activates and the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation, Mol. Endocrinol., 20, 268-278
  • Koller, E., Propp, S., Zhang, H., Zhao, C., Xiao, X., Chang, M.Y., Hirsch, S.A., Shepard, P.J., Koo, S., Murphy, C., Glazer, R.I., Dean, N.M. (2006) Use of a chemically modified antisense oligonucelotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development, Cancer Res., 66, 2059-2066
  • Liang, K., Lu, Y., Zeng, X., Glazer, R.I., Mills, G.B., Fan, Z. (2006) Differential roles of PDK1 and Akt1 expression and phosphorylation in breast cancer cell resistance to paclitaxel, doxorubicin and gemcitabine, Mol. Pharmacol., 70, 1-45-1052
  • Xie, Z., Yuan, H., Yin, Y., Bai, R., Glazer, R.I. (2006) 3-Phosphoinositide-dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases, BMC Cancer, 6, 77-88
  • Yin, Y., Russell, R.G., Dettin, L.E., Bai, R., Wei, Z.-L., Kozikowski, A.P., Kopelovich, L., Glazer, R.I., Peroxisome Proliferator-Activated Receptor Delta and Gamma Agonists Differentiallty Alter Tumor Differentiation and Progression During Mammary Carcinogenesis, Cancer Res., 65, 3950-57, 2005
  • Yin, Y., Bai, R., Russell, R.G., Beildeck, M.E., Xie, Z., Kopelovich, L., Glazer, R.I., Characterization of Medroxyprogesterone and DMBA-Induced Mammary Tumors By Gene Expression Profiling, Mol. Carcinogenesis, 44, 42-50, 2005
  • Zhan, M., Yu, D., Liu, J., Glazer, R.I., Hannay, J., Pollock, R.E. (2005) Transcriptional repression of protein kinase C-alpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation, J. Biol. Chem., 280, 4825-4833
  • Smithgall, T.E., Glazer, R.I. (2004) c-fes proto-oncogene, Encyclopedia of Biol. Chem., 1, 377-382
  • Wei, Z.L., Petukhov, P.A., Bizik, F., Teixeira, J.C., Mercola, M., Volpe, E., Glazer, R.I., Willson, T.M., Kozikowski, A.P. (2004) Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis and effects on cardiomyocyte differentiation, J. Am. Chem. Soc., 126, 16714-16715
  • Xie, Z., Zeng, X., Waldman, T. , Glazer, R.I. (2003) Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1, Cancer Res., 63, 5370-5375
  • Ackler S., Ahmad S., Tobias C., Johnson M.D., Glazer R.I. (2002) Delayed mammary gland involution in MMTV-AKT1 transgenic mice, Oncogene, 21, 198-206
  • Zeng X., Xu H., Glazer R.I. (2002) Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha, Cancer Res., 62 (12), 3538-43
  • Kopelovich, L., Fay, J.R., Glazer, R.I., Crowell, J.A. (2002) Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents, Mol. Cancer Ther., 1, 357-363
  • Clark, J.H., Haridasse, V. , Glazer, R.I., Modulation of the Human Protein Kinase C-alpha Gene Promoter by Activator Protein-2, Biochemistry, 41, 11847-11856, 2002
  • Clark, J.H., Haridasse, V., Glazer, R.I. (2002) Modulation of the human protein kinase C-alpha gene promoter by activator protein-2, Biochemistry, 41, 11847-11856
  • Park B.K., Zeng X., Glazer R.I. (2001) Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells, Cancer Res., 61, 7647-53
  • Bansal, R., Chen, H.X., Marshall, J.L., Tan, J., Glazer, R.I. (2001) Detection of mixed-backbone oligonucleotide (GEM 231) in liver and tumor tissues by capillary electrophoresis, J. Chromatography B, 750, 129-135

Profile Details

Last Updated: 3/28/2009

COS Expertise ID #535347
Reference this profile directly: http://myprofile.cos.com/glazerr47